Kennedy A W
Department of Gynecology, Cleveland Clinic Foundation, OH 44195, USA.
Semin Oncol. 1995 Apr;22(2):161-5.
The management of GTD has developed as a result of an accurate and sensitive serologic marker, effective chemotherapeutic agents, and the judicious treatment of patients with evidence of persistence. Treatment and intervention guidelines are well established and will lead to a successful outcome for nearly all patients. Reproductive potential can be preserved and chemotherapy toxicity has been made quite manageable in the minority of patients requiring its administration. However, as demonstrated in the patient whose case is presented, violation or deviation from these guidelines for monitoring and intervention can lead to the unnecessary sacrifice of reproductive capability and the administration of potentially toxic multiagent chemotherapy regimens.
妊娠滋养细胞疾病（GTD）的管理方法是由于出现了一种准确且敏感的血清学标志物、有效的化疗药物以及对有持续性证据患者的合理治疗而得以发展的。治疗和干预指南已经确立完善，几乎所有患者都能因此获得成功的治疗结果。生育潜能可以得到保留，并且在少数需要化疗的患者中，化疗毒性也已变得相当可控。然而，正如本文所呈现病例的患者那样，违反或偏离这些监测和干预指南可能会导致生育能力被不必要地牺牲，以及使用可能有毒的多药化疗方案。
